Market Cap 58.38M
Revenue (ttm) 3.95M
Net Income (ttm) -131.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,321.77%
Debt to Equity Ratio 0.00
Volume 52,900
Avg Vol 83,488
Day's Range N/A - N/A
Shares Out 6.15M
Stochastic %K 30%
Beta 2.77
Analysts Strong Sell
Price Target $95.00

Company Profile

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-12575...

Industry: Biotechnology
Sector: Healthcare
Phone: 800-466-6059
Address:
One Corporate Drive, 2nd Floor, South San Francisco, United States
Bwnuts
Bwnuts Oct. 24 at 7:47 PM
$ALGS did I mention perpetual underperformance?
0 · Reply
Bwnuts
Bwnuts Oct. 24 at 1:02 AM
$ALGS was at #3 for most of the year. Now it’s at #4. There’s between 600-700 public biotech stocks and $ALGS is the 4th worst. You could throw a dart at the bevy of options and your chances would be exponentially better than this dog.
1 · Reply
Bwnuts
Bwnuts Oct. 24 at 12:58 AM
$ALGS perpetual underperformance. Absolutely terrible stock which basically means absolutely terrible company. This is BK within 12 months.
0 · Reply
Quantumup
Quantumup Oct. 21 at 8:31 PM
Clear Street🏁 $SGMT Buy/$29 $MDGL Boston Pharma - $GSK $IVA VKTX $ALGS Clear Street said: We initiate coverage of SGMT with a Buy, reflecting the highly attractive profile of once-daily oral denifanstat—an asset leveraging robust multi-modal biology akin to FGF21 analogs, which have recently driven prominent M&A activity within the MASH space. Denifanstat's exceptional P2b F2-F3 data, outstanding P3 acne results, and forward-looking development plans for F4C in combination with Madrigal Pharmaceuticals' (MDGL: Nasdaq, Buy, $431 PT) REZDIFFRA, all underpinned by a solid $135.5M cash position (runway into 2027), and anticipated readouts from ongoing P1 trials, together position SGMT as a compelling growth story. Even under conservative valuation metrics, comparable to Boston Pharma's recent $1.2B upfront acquisition, our $29 PT implies substantial upside relative to SGMT's current $188M EV.
0 · Reply
aletz
aletz Oct. 21 at 1:18 PM
$ALGS all the antigens have not rebounded significantly and stayed almost the same level it left after stopping taking pevy, absolutely ground breaking compared to the current standard of care. Big pharmas will be watching very closely, but ALGS has no interest of letting pevy go now. $GSK $RHHBY $GILD
1 · Reply
aletz
aletz Oct. 21 at 1:15 PM
$ALGS For serious investors, you can have a sneak peak at AASLD abstract already. Results are astonishing. Aligos team and CEO are absolutely confident that pevy (formely ALG-000184) will change the paradigm of CHB treatment, and so am I.
0 · Reply
aletz
aletz Oct. 21 at 1:13 PM
$ALGS For any long, I strongly recommend watching this latest presentation. Some new timeline 1H 2026 for B-SUPREME HBeAg- 12wk data 2H 2026 for B-SUPREME HBeAg+ 24wk data (and possibly more expanded interim data) 1H2026 possibly partnership deal for MASH asset (good to have, but realistically the competition is really wild in MASH currently, and phase 2a is way behind all the competition) https://journey.ct.events/view/7252d41f-6d94-4f3d-8f85-d75fc1fe6cc7 Exciting though, very exciting
0 · Reply
Zezed1
Zezed1 Oct. 21 at 11:19 AM
$ALGS waiting for 50 on this one
0 · Reply
IPOARMY1
IPOARMY1 Oct. 21 at 1:01 AM
$ALGS 👂 https://investor.aligos.com/news-and-media/presentations-and-events
0 · Reply
IPOARMY1
IPOARMY1 Oct. 16 at 3:29 PM
$ALGS $1M block 👀
1 · Reply
Latest News on ALGS
Aligos Therapeutics Presents Positive Data at APASL 2025

Mar 26, 2025, 8:00 AM EDT - 7 months ago

Aligos Therapeutics Presents Positive Data at APASL 2025


Aligos Therapeutics Announces Reverse Stock Split

Aug 15, 2024, 9:00 AM EDT - 1 year ago

Aligos Therapeutics Announces Reverse Stock Split


Bwnuts
Bwnuts Oct. 24 at 7:47 PM
$ALGS did I mention perpetual underperformance?
0 · Reply
Bwnuts
Bwnuts Oct. 24 at 1:02 AM
$ALGS was at #3 for most of the year. Now it’s at #4. There’s between 600-700 public biotech stocks and $ALGS is the 4th worst. You could throw a dart at the bevy of options and your chances would be exponentially better than this dog.
1 · Reply
Bwnuts
Bwnuts Oct. 24 at 12:58 AM
$ALGS perpetual underperformance. Absolutely terrible stock which basically means absolutely terrible company. This is BK within 12 months.
0 · Reply
Quantumup
Quantumup Oct. 21 at 8:31 PM
Clear Street🏁 $SGMT Buy/$29 $MDGL Boston Pharma - $GSK $IVA VKTX $ALGS Clear Street said: We initiate coverage of SGMT with a Buy, reflecting the highly attractive profile of once-daily oral denifanstat—an asset leveraging robust multi-modal biology akin to FGF21 analogs, which have recently driven prominent M&A activity within the MASH space. Denifanstat's exceptional P2b F2-F3 data, outstanding P3 acne results, and forward-looking development plans for F4C in combination with Madrigal Pharmaceuticals' (MDGL: Nasdaq, Buy, $431 PT) REZDIFFRA, all underpinned by a solid $135.5M cash position (runway into 2027), and anticipated readouts from ongoing P1 trials, together position SGMT as a compelling growth story. Even under conservative valuation metrics, comparable to Boston Pharma's recent $1.2B upfront acquisition, our $29 PT implies substantial upside relative to SGMT's current $188M EV.
0 · Reply
aletz
aletz Oct. 21 at 1:18 PM
$ALGS all the antigens have not rebounded significantly and stayed almost the same level it left after stopping taking pevy, absolutely ground breaking compared to the current standard of care. Big pharmas will be watching very closely, but ALGS has no interest of letting pevy go now. $GSK $RHHBY $GILD
1 · Reply
aletz
aletz Oct. 21 at 1:15 PM
$ALGS For serious investors, you can have a sneak peak at AASLD abstract already. Results are astonishing. Aligos team and CEO are absolutely confident that pevy (formely ALG-000184) will change the paradigm of CHB treatment, and so am I.
0 · Reply
aletz
aletz Oct. 21 at 1:13 PM
$ALGS For any long, I strongly recommend watching this latest presentation. Some new timeline 1H 2026 for B-SUPREME HBeAg- 12wk data 2H 2026 for B-SUPREME HBeAg+ 24wk data (and possibly more expanded interim data) 1H2026 possibly partnership deal for MASH asset (good to have, but realistically the competition is really wild in MASH currently, and phase 2a is way behind all the competition) https://journey.ct.events/view/7252d41f-6d94-4f3d-8f85-d75fc1fe6cc7 Exciting though, very exciting
0 · Reply
Zezed1
Zezed1 Oct. 21 at 11:19 AM
$ALGS waiting for 50 on this one
0 · Reply
IPOARMY1
IPOARMY1 Oct. 21 at 1:01 AM
$ALGS 👂 https://investor.aligos.com/news-and-media/presentations-and-events
0 · Reply
IPOARMY1
IPOARMY1 Oct. 16 at 3:29 PM
$ALGS $1M block 👀
1 · Reply
IPOARMY1
IPOARMY1 Oct. 16 at 6:34 AM
$ALGS I'm sure they'll mention the ongoing partner discussions for ALG-055009. COMMENT!! https://www.linkedin.com/posts/aligos-therapeutics_hcwainwright-liverdisease-activity-7383881763854610434-B5su?utm_source=share&utm_medium=member_android&rcm=ACoAAEgbePIBp_paWBxNo4iRhPf9Z2HFQMhYCjI
0 · Reply
EyeingTheDips
EyeingTheDips Oct. 15 at 11:32 AM
$RVPH Catalysts Driving Squeeze Risk Upcoming events could ignite covering: November 6-7, 2025: Open-Label Extension (OLE) data presentation for brilaroxazine (schizophrenia drug). November 11-12, 2025: BIO CEO & Investor Conference for visibility. November 17, 2025: Q3 earnings report. December 9, 2025: Neuro Innovation Forum discussing clinical programs. Q4 2025 / Early Q1 2026: Phase 3 interim data readout for brilaroxazine, a major value driver. Recent: $9 million offering (September 2025) and OLE trial completion boosted a 21% surge, with positive data showing efficacy and biomarker improvements. Positive outcomes (e.g., robust efficacy, low discontinuation) could mirror peers like $DRUG or $ALGS, triggering parabolic moves. Buyout chatter adds upside, given $83 million cap vs. acquisitions like $KRTX ($14B).
0 · Reply
Quantumup
Quantumup Oct. 14 at 8:16 PM
Truist🏁 $MDGL Buy/$580 and says, KOL Feedback Shows High Interest in Rezdiffra and Supports Peak Sales of $6.2B, in its View. $IVA $NVO $VKTX $ALGS Truist said in its MDGL initiation: Key investment points - 1) First drug approved (Rezdiffra) for MASH with early launch metrics indicating high demand & potential for upside from continued strong launch; 2) Sizable opportunity in MASH (10-20M US patients) not fully reflected at current levels; 3) KOL feedback shows high interest in Rezdiffra, in our view supports peak sales of $6.2B vs. $4.5B cons (2036E) in the approved F2/F3 subtype; 4) Potential for upside in MASH F4 subtype (data 2027E); 5) Rezdiffra market exclusivity likely longer than Street models; and 6) Potential M&A target, given recent Big Pharma interest in MASH.
0 · Reply
aletz
aletz Oct. 13 at 8:18 PM
$ALGS https://www.biostockinfo.com/algs-part4/ My final piece on ALGS, seriously undervalued gem
0 · Reply
Bwnuts
Bwnuts Oct. 13 at 3:54 PM
$ALGS will it hold? Test of lower channel.
0 · Reply
IPOARMY1
IPOARMY1 Oct. 10 at 1:42 PM
$ALGS https://tipranks.onelink.me/WJho/aj4qrm87
0 · Reply
bginvest
bginvest Oct. 10 at 10:32 AM
$AKRO $ALGS $IVA $MDGL $NVO the big institutional investors have a PT of 1000dkr on a Danish biotech company in the same sector that’s Zealand Pharma 📈🤔🤷‍♂️
0 · Reply
Quantumup
Quantumup Oct. 10 at 10:08 AM
Oppenheimer⬆️ $MDGL's PT to $590 from $500 and reiterated at an Outperform rating. $NVO $AKRO $IVA $ALGS Oppenheimer said: With Novo Nordisk announcing plans to acquire Akero Therapeutics, the importance of combinations moves to the forefront for MASH investors along three key dimensions: 1) combination approaches to treating MASH with orthogonal and complementary mechanisms; 2) combination of portfolios to address a broad range of MASH patients including F2-F3 and F4; and 3) combination of corporate entities developing and commercializing MASH therapeutics to optimize capabilities and outcomes. While some investors were apparently disappointed that MDGL was not acquired, we see favorable points of read-across: 1) Rezdiffra is already entrenched as a foundational therapy to be considered for any oral combination MASH regimens; and 2) MDGL has acquired a GLP-1 as SYH2086 has all the properties required for a daily oral combo.
0 · Reply
IPOARMY1
IPOARMY1 Oct. 9 at 8:10 PM
$ALGS they're buying up the MASH drugs $NVO $AKRO $ETNB
0 · Reply
Quantumup
Quantumup Oct. 9 at 12:23 PM
Stifel reiterated $IVA Buy/$17 $MDGL $NVO $VKTX $ALGS Stifel said in its note:
0 · Reply
Bwnuts
Bwnuts Oct. 8 at 11:43 PM
$ALGS Short attack incoming I suspect.
0 · Reply
Bwnuts
Bwnuts Oct. 7 at 7:07 PM
$ALGS heading for a bearish engulfing candle today. Every time this has happened in the past, next few days have been awful. @Cajo0404 is lurking so you know he’ll be working it downward.
1 · Reply